Figure 2
Endogenous Epo levels and flow cytometry of myeloid blasts as biomarkers in the prediction of response to Epo/G-CSF treatment in low-/intermediate-I–risk MDS. Points granted for Epo level in this model are exactly as in the validated model of Hellström-Lindberg et al.9 Normal and aberrant FCM score 0 and −2 points, respectively. Applying this new model defines 3 subgroups with 94%, 17%, and 11% probability to respond to growth factor treatment.
